Interestingly, we found no significant difference in survival probability in patents with diverse levels of CHK1 in ER- or PR- breast cancer, but we did find such a difference in ER+ or PR+ patients (Figure 6I, J). This evidence concerns the gene CHEK1 and breast cancer.